Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.